What the FDA labels say about taking them together
Foscarbidopa/foslevodopa and tranylcypromine
Foscarbidopa/foslevodopa's FDA label of March 19, 2026 names tranylcypromine in its drug interactions section; the tranylcypromine label PlainMeds reads does not name foscarbidopa/foslevodopa. The foscarbidopa/foslevodopa label: “Oxidase (MAO) Inhibitors Nonselective MAO Inhibitors The use of nonselective MAO inhibitors with VYALEV is contraindicated.”
Check it at the source: the foscarbidopa/foslevodopa FDA label on DailyMed (effective March 19, 2026, AbbVie Inc.); the tranylcypromine FDA label on DailyMed (effective July 2, 2025, Advanz Pharma (US) Corp.).
What does the foscarbidopa/foslevodopa label say about tranylcypromine?
Foscarbidopa/foslevodopa label, drug interactionsOxidase (MAO) Inhibitors Nonselective MAO Inhibitors The use of nonselective MAO inhibitors (e.g., phenelzine and tranylcypromine) with VYALEV is contraindicated [see Contraindications ( 4 ) ].
Source: FDA drug label (Vyalev), AbbVie Inc., effective March 19, 2026 (SPL set 28e806e4-951c-40a9-9f0c-d0929caf054c), via openFDA; the full label on DailyMed
What does the tranylcypromine label say about foscarbidopa/foslevodopa?
Tranylcypromine's label (effective July 2, 2025) does not name foscarbidopa/foslevodopa in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (PARNATE), Advanz Pharma (US) Corp., effective July 2, 2025 (SPL set b72d8187-dfcc-4ea0-b5e9-c0be95b69a27), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Foscarbidopa/foslevodopa | Tranylcypromine | |
|---|---|---|
| Labeled for | Parkinson's disease | Depression |
| Boxed warning | No | Yes |
| Pharmacy cost (NADAC) | n/a | $0.591 per tablet 10 mg tablet |
| Shortage now | No current entry | A presentation being discontinued |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once